Little-known biotech company is making waves for its unique involvement in the regenerative medicine landscape.
Regenerative medicine continues to find its way into the mainstream…. It’s an exciting topic on Wall Street. Enormous amounts have been invested in stem cell therapy research for decades. This Stock may be flying under the radar right now, but could soon gain major attention for what it is uniquely doing. The company harnesses elements of perinatal tissue derived from the human placenta for manufacturing structural tissue allografts to heal wounds. Its products have the potential to save millions of lives while building market capitalization growth in the process.
Excitingly they have been approved for an Investigational Review Board (IRB) sanctioned clinical study. This study aims to investigate the utilization and effects of the company’s Vendaje line in diabetic patients suffering from foot ulcers. VENDAJE, a dehydrated placental allograft that can be used for advanced wound care as a substitute for skin grafts or placed over open wounds to speed up and improve the healing process after surgery. Diabetic Foot Ulcers are a significant risk for people with diabetes. According to the American Podiatric Medical Association (APMA), a leading resource for foot and ankle health, approximately 15 percent of people with diabetes develop foot ulcers. Of those 15 percent, six percent go on to be hospitalized due to infection or other ulcer-related complications. The risk to patients with diabetes is significant, as it is the leading cause of lower extremity amputations in the U.S. Approximately 14 to 24 percent of people with diabetes who develop foot ulcers will require an amputation.
Thank you for subscribing to Insider Trades Daily, which covers the most recent insider buying and selling activity from Wall Street CEO's, CFO's, COO's and other insiders.
This message is a paid advertisement sent on behalf of Huge Alerts, a third-party advertiser of InsiderTrades.com and MarketBeat.
This message is a paid advertisement for BioStem Technologies Inc. (OTC: BSEM) from Sideways Frequency and Huge Alerts. American Consumer News, LLC dba MarketBeat receives a fixed fee for each subscriber that clicks on a link in this email, totaling up to $12,600. Other than the compensation received for this advertisement sent to subscribers, MarketBeat and its principals are not affiliated with either Sideways Frequency or Huge Alerts. MarketBeat and its principals do not own any of the stocks mentioned in this email or in the article that this email links to. Neither MarketBeat nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from MarketBeat to buy or sell any security. MarketBeat has not evaluated the accuracy of any claims made in this advertisement. MarketBeat recommends that investors do their own independent research and consult with a qualified investment professional before buying or selling any security. Investing is inherently risky. Past-performance is not indicative of future results. Please see the disclaimer regarding BioStem Technologies Inc. (OTC: BSEM) on Huge Alerts' website for additional information about the relationship between Huge Alerts and BioStem Technologies Inc. (OTC: BSEM).
If you have questions about your subscription, feel free to contact our U.S. based support team via email at contact@marketbeat.com or leave us a voicemail at (844) 978-6257.
If you no longer wish to receive email from InsiderTrades.com, you can unsubscribe.
Post a Comment
Post a Comment